Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Sidney Lerfald

Psychiatry Charleston, WV Medical Doctor

NPI 1932163979 CMS profile 359725

415 Morris Street, Suite 306, Charleston, WV 25301

Open in the dashboard

General payments

$14,435

76 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Sidney Lerfald of Charleston, WV is reported in the CMS Open Payments database as having received $14,435 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $14,435 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sidney Lerfald
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Sidney Lerfald were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Sidney Lerfald Psychiatry median Middle half National median
2019 $14,435 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program year 2019
  1. Sunovion Pharmaceuticals Inc. $8,375 18 payments
  2. Otsuka America Pharmaceutical, Inc. $4,959 18 payments
  3. Teva Pharmaceuticals USA, Inc. $179 8 payments
  4. Allergan Inc. $165 9 payments
  5. Amgen Inc. $150 5 payments
  6. Janssen Pharmaceuticals, Inc $149 3 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $133 5 payments
  8. Jazz Pharmaceuticals Inc. $89 1 payment
  9. Otsuka Pharmaceutical Development & Commercialization, Inc. $80 1 payment
  10. Lundbeck LLC $74 4 payments
  11. Other $81 4 payments

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,247 7 payments
  2. Food and Beverage $1,777 65 payments
  3. Travel and Lodging $410 3 payments
  4. Education $2 1 payment
Products named General payments · program year 2019
  1. LATUDA $8,375 18 payments
  2. REXULTI Psychiatry $4,862 17 payments
  3. VRAYLAR $165 9 payments
  4. AIMOVIG $150 5 payments
  5. SPRAVATO $149 3 payments
  6. AUSTEDO $144 5 payments
  7. ABILIFY MAINTENA $98 1 payment
  8. TRINTELLIX $89 1 payment
  9. XYREM $89 1 payment
  10. REXULTI Psychiatry $54 3 payments
  11. Other $181 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record